Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 11/20 | 0.43 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25737034 | 0.78 | EGFR (0.43) | FGFR1 | |
| SCHEMBL25737033 | 0.72 | SMN1; SMN2 (0.55) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL7917887 | 0.70 | CA12 (0.52) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL25735906 | 0.70 | SMN1; SMN2 (0.68) | TGM2LMNAKDM4EMAPT | |
| SCHEMBL17481245 | 0.69 | FTO (0.52) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL439369 | 0.69 | TGM2 (0.79) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL8029533 | 0.67 | RAB9A (0.65) | PPARGTGM2LMNAKDM4EMAPT | |
| SCHEMBL4103284 | 0.66 | TGM2 (0.76) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL30862483 | 0.66 | CA12 (0.71) | KDM4E | |
| SCHEMBL7917363 | 0.66 | CA12 (0.71) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | PPARG 3282/4885TGM2 2103/4885F13A1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.